why choose us

First received: September 15, 2023

Clinical Trial: Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Breast Cancer

Study Type: INTERVENTIONAL


Official Title: Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With

Brief Summary: The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors.The main question[s] it aims to answer are:to evaluate the safety and tolerability of single agent and combination therapyto determine the recommended dose for Phase 2 of single agent and combination therapyto determine the pharmacokinetics of TNG348 as a single agent and in combination therapyto…

Read more